Anzeige
Mehr »
Mittwoch, 30.07.2025 - Börsentäglich über 12.000 News
Geheime Millionen-Käufe in Bitcoin & Altcoins - ohne Wallet, ohne Risiko? Jetzt wird's spannend
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PNH3 | ISIN: US14843C1053 | Ticker-Symbol:
NASDAQ
30.07.25 | 20:29
16,280 US-Dollar
+0,18 % +0,030
1-Jahres-Chart
CASTLE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
CASTLE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur CASTLE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCastle Biosciences, Inc.: Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal1
23.07.Castle Biosciences stock jumps after FDA grants Breakthrough Device status2
23.07.Castle Biosciences, Revolution Medicines get FDA breakthrough statuses3
23.07.Castle Biosciences Gets Breakthrough Device Status For DecisionDx-Melanoma Test1
23.07.Castle Biosciences, Inc.: FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx-Melanoma Test598FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its...
► Artikel lesen
17.07.Castle Biosciences, Inc.: Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture2
CASTLE BIOSCIENCES Aktie jetzt für 0€ handeln
19.06.Castle Biosciences, Inc.: Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)225FRIENDSWOOD, Texas, June 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on...
► Artikel lesen
17.06.Castle Biosciences stock steady as Canaccord reiterates buy rating3
17.06.SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30306STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed...
► Artikel lesen
16.06.Castle Biosciences partners with SciBase for diagnostic tests1
16.06.Castle Biosciences partners with SciBase to develop atopic dermatitis test1
16.06.Castle Biosciences, Inc.: Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases121FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it...
► Artikel lesen
11.06.Castle Biosciences, Inc.: Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention1
29.05.Castle Biosciences, Inc.: New Data at ASCO 2025 Affirms DecisionDx-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes2
23.05.Castle Biosciences ändert Satzung, Aktionäre stimmen ab2
23.05.CASTLE BIOSCIENCES INC - 8-K, Current Report1
21.05.Scotiabank cuts Castle Biosciences target to $40, maintains rating5
09.05.Castle Biosciences bestätigt Wirksamkeit des UM-Tests1
09.05.Castle Biosciences confirms UM test's efficacy3
09.05.Castle Biosciences, Inc.: Real-World Study Confirms Long-Term Performance of DecisionDx-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM ...233FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data...
► Artikel lesen
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1